Tech Company Financing Transactions

Transave Funding Round

Easton Capital, F-Prime Capital and Prospect Venture Partners invested in a $17.8 million venture round for Transave. The funding round closed on 3/31/2006.

Transaction Overview

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

11 Deer Park Drive 117
Monmouth Junction, NJ 08852
USA

Phone

(732) 438-9434

Website

www.transaveinc.com

Email Address

Not Recorded

Overview

TRANSAVE is a biotechnology company whose mission is to improve the treatment of serious lung diseases through the development of novel, site-specific liposomal drug products.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Timothy Whitten

        

Chief Financial Officer

Michio Soga

        

Chief Medical Officer

Renu Gupta

        

Chief Technical Officer

Walter Perkins

        

Vice President

Eric Dadey

        

VP - Operations

Nicholas Gurreri

        

Browse more venture capital transactions:

Prev: 3/31/2006: ProLacta BioSciences venture capital transaction
Next: 3/31/2006: Ablation Frontiers venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary